D.A. Davidson & CO. Raises Stock Holdings in Stryker Co. (NYSE:SYK)

D.A. Davidson & CO. grew its stake in shares of Stryker Co. (NYSE:SYK) by 0.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,574 shares of the medical technology company’s stock after buying an additional 451 shares during the period. D.A. Davidson & CO.’s holdings in Stryker were worth $29,731,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. Dunhill Financial LLC lifted its holdings in Stryker by 94.9% during the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in shares of Stryker during the 3rd quarter valued at $36,000. Activest Wealth Management purchased a new position in shares of Stryker during the 4th quarter valued at $36,000. Crews Bank & Trust bought a new position in Stryker in the 4th quarter worth $39,000. Finally, Hara Capital LLC purchased a new stake in Stryker in the 3rd quarter worth $42,000. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 0.9 %

Shares of Stryker stock opened at $385.05 on Tuesday. The stock has a market cap of $146.79 billion, a price-to-earnings ratio of 49.62, a PEG ratio of 2.98 and a beta of 0.96. The firm’s 50-day moving average is $377.31 and its two-hundred day moving average is $367.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 1 year low of $314.93 and a 1 year high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings results on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, topping the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business posted $3.46 earnings per share. As a group, research analysts expect that Stryker Co. will post 13.49 earnings per share for the current fiscal year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be given a $0.84 dividend. This represents a $3.36 annualized dividend and a dividend yield of 0.87%. The ex-dividend date is Monday, March 31st. Stryker’s payout ratio is 43.30%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on SYK shares. StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, January 30th. Stifel Nicolaus raised their target price on shares of Stryker from $400.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. BTIG Research lifted their price objective on Stryker from $383.00 to $394.00 and gave the stock a “buy” rating in a research note on Wednesday, October 30th. Canaccord Genuity Group upped their target price on shares of Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research report on Wednesday, January 29th. Finally, JPMorgan Chase & Co. increased their price target on Stryker from $420.00 to $445.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Five equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $420.68.

Insider Activity

In other Stryker news, Director Ronda E. Stryker sold 201,392 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the completion of the transaction, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.